The new insights on the pathogenesis of sJIA have therefore dramatically changed the approach to treatment, with the development of targeted treatments (anti-IL-1 and anti-IL-6 agents) more effective and safer than earlier medications. This evidence concerns the gene IL1B and systemic-onset juvenile idiopathic arthritis.